Autonomix Medical, Inc. — Form 8-K
Filed September 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 67/100
What the filing says
Sandra Cohen Kalter, former Vice President and Chief Regulatory Counsel at Medtronic with 20 years tenure, appointed to Autonomix Medical's Board of Directors on September 16, 2026. Kalter brings 40+ years of MedTech experience, including oversight of 27+ acquisitions and regulatory work on renal denervation and electrophysiology platforms. She will provide strategic guidance on FDA pathways, technology development, and industry partnerships.
Why this rating
Board appointment adds FDA/regulatory credibility and M&A integration expertise highly relevant to $6.3M pre-revenue company seeking partnerships. Meaningful but not transformational—no cash infusion or revenue impact disclosed.
See more from September 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.